NASDAQ:GNCA
Delisted
Genocea Biosciences Stock News
$0.0001
+0 (+0%)
At Close: Apr 19, 2023
Genocea Biosciences, Inc. (GNCA) CEO Chip Clark on Q1 2021 Results - Earnings Call Transcript
05:09pm, Thursday, 29'th Apr 2021
Genocea Biosciences, Inc. (GNCA) CEO Chip Clark on Q1 2021 Results - Earnings Call Transcript
Genocea To Host First Quarter 2021 Corporate Update Conference Call & Webcast
04:30pm, Thursday, 22'nd Apr 2021
CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its first qu
New Strong Sell Stocks for April 13th
11:22am, Tuesday, 13'th Apr 2021
ASC, BCEI, XOG, GNCA, and GNLN have been added to the Zacks Rank #5 (Strong Sell) List on April 13, 2021
Genocea to Present Novel Preclinical Inhibigen™ Data at AACR Annual Meeting 2021
08:30am, Saturday, 10'th Apr 2021
Pro-tumor effects detected as early as four days after Inhibigen administration
Genocea to Present at the 20th Annual Needham Virtual Healthcare Conference
04:30pm, Tuesday, 06'th Apr 2021
CAMBRIDGE, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that C
Genocea Provides Fourth Quarter 2020 Corporate Update
07:30am, Thursday, 11'th Feb 2021
GEN-011 and GEN-009 clinical trials continue to advance
Genocea to Host Fourth Quarter 2020 Corporate Update Conference Call & Webcast
04:05pm, Thursday, 04'th Feb 2021
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its fourth qu
Genocea Announces Publication in Cancer Discovery Highlighting the Advantages of Neoantigen Identification with the ATLAS™ Platform
06:00am, Thursday, 28'th Jan 2021
Study validates ATLAS bioassay for developing patient-specific cancer immunotherapies by including neoantigensof anti-tumor T cell responses and excluding Inhibigens™, or neoantigens of pro-tumor T
Genocea to Participate in the B. Riley Securities' Virtual Oncology Investor Conference
06:54pm, Tuesday, 19'th Jan 2021
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that C
Genocea to Present at the H.C. Wainwright Virtual BioConnect Conference
04:19pm, Monday, 04'th Jan 2021
CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that
Is the Options Market Predicting a Spike in Genocea (GNCA) Stock?
09:47am, Monday, 28'th Dec 2020
Investors need to pay close attention to Genocea (GNCA) stock based on the movements in the options market lately.
Novel clinical and durable immune response patterns suggest addition of GEN-009 may offer additive clinical benefit in combination with PD-1-based therapies
Genocea to Host Investor Call Highlighting New GEN-009 Clinical and Immunogenicity Data to be Presented at Virtual SITC 2020
06:10pm, Thursday, 05'th Nov 2020
Call scheduled for November 9th at 8:30 a.m. EST Call scheduled for November 9th at 8:30 a.m. EST
Genocea Biosciences, Inc's (GNCA) CEO Chip Clark on Q3 2020 Results - Earnings Call Transcript
01:24pm, Thursday, 29'th Oct 2020
Genocea Biosciences, Inc's (GNCA) CEO Chip Clark on Q3 2020 Results - Earnings Call Transcript
Genesis: The Domino In The Skilled Nursing Segment (NYSE:GEN)
05:52pm, Friday, 25'th Sep 2020
Genesis Healthcare is a dangerous stock that's hemorrhaging big losses. The last quarter was extremely bad.
